Artiva halts AlloNK development due to safety and cost concerns.
Artiva halted development of its cell therapy AlloNK and slashed its workforce by 94% to explore strategic alternatives, citing clinical data failures and safety events.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed